JP2009526829A - 流涎症の治療のためのアルファ−2受容体アゴニスト(クロニジン)と抗ムスカリン剤(オキシブチニン)との組み合わせ - Google Patents
流涎症の治療のためのアルファ−2受容体アゴニスト(クロニジン)と抗ムスカリン剤(オキシブチニン)との組み合わせ Download PDFInfo
- Publication number
- JP2009526829A JP2009526829A JP2008554857A JP2008554857A JP2009526829A JP 2009526829 A JP2009526829 A JP 2009526829A JP 2008554857 A JP2008554857 A JP 2008554857A JP 2008554857 A JP2008554857 A JP 2008554857A JP 2009526829 A JP2009526829 A JP 2009526829A
- Authority
- JP
- Japan
- Prior art keywords
- fluency
- antimuscarinic agent
- clonidine
- oxybutynin
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、抗ムスカリン剤とα2−アドレナリン受容体アゴニストとの組み合わせが流涎症の治療に有用であるという知見に基づくものである。かかる組み合わせは、改善作用及び/又は軽減した副作用を示す。この2つの薬剤は、一緒に、単一の組成物として、あるいは同時に、又は連続して投与してもよい。
本発明で使用するのに好ましいα2−アドレナリン受容体アゴニストは、クロニジン、アプラクロニジン、ブリモニジン、リルメジニド(rilmedinide)、デクスメデトミジン、チザニジン、モノキシジン(monoxdine)及びロフェキシジンがある。本発明で使用するのに好ましい抗ムスカリン剤は、トルテロジン、ダリフェナシン、ソリフェナシン、ザミフェナシン、オキシブチニン、トロスピウム、レバトロパン酸、チオトロピウム及びRo−3202904(PSD−506)がある。
本研究では、9人の健常男性のボランティアにおける唾液の分泌に対するクロニジンとオキシブチニンの効果を試験した。非盲検で、非無作為化された二期間の用量漸増(rising dose)法を使用した。
深刻又は重篤な有害事象は報告されなかった。最も一般的に起こる有害事象は頭痛と疲労であった。本研究の間、生化学、血液学及び尿検査の結果に対して臨床上重大な変化は観察されなかった。本研究の間、バイタルサイン(例えば血圧)、身体検査又は12リードECGに対する臨床上の重大な変化は観察されなかった。
Claims (15)
- 流涎症の治療における別々、同時又は連続の使用のための混合製剤としての、α2−アドレナリン受容体アゴニストと抗ムスカリン剤を含んで成る製品。
- 前記アゴニストが舌の側面、舌下又は頬側のルートから投与される、請求項1に記載の製品。
- 前記アゴニストが、ガム、スプレー、香錠、トローチ又は分散錠として調製される、請求項1又は2に記載の製品。
- 前記アゴニストがクロニジン、アプラクロニジン、ブリモニジン、リルメジニド、デクスメデトミジン、チザニジン、モノキシジン及びロフェキシジンから選択される、請求項1〜3のいずれか1項に記載の製品。
- 前記抗ムスカリン剤がダリフェナシン、ソリフェナシン、ザミフェナシン、オキシブチニン、グリコピロラート、トロスピウム、トルテロジン、フェソテロジン、レバトロパン酸、Ro−3202904、イプラトロピウム及びチオトロピウムから選択される、請求項1〜4のいずれか1項に記載の製品。
- 粘液溶解物質を更に含んで成る、請求項1〜5のいずれか1項に記載の製品。
- 前記粘液溶解物質がメントール又はユーカリ油である、請求項6に記載の製品。
- 流涎症の治療のための薬物の製造のためのα2アドレナリン受容体アゴニストの使用であって、前記薬物が、舌の側面、舌下又は頬側のルートから投与され、治療されるべき患者が、抗ムスカリン剤による治療を受けている、使用。
- 流涎症の治療のための薬物の製造のための抗ムスカリン剤の使用であって、治療されるべき患者が、舌の側面、舌下又は頬側のルートから投与されるα2アドレナリン受容体アゴニストによる治療を受けている、使用。
- 前記薬物が、ガム、スプレー、香錠、トローチ又は分散錠として調製される、請求項8又は9に記載の使用。
- 前記アゴニストがクロニジン、アプラクロニジン、ブリモニジン、リルメジニド、デクスメデトミジン、チザニジン、モノキシジン及びロフェキシジンから選択される、請求項8〜10のいずれか1項に記載の使用。
- 前記抗ムスカリン剤がダリフェナシン、ソリフェナシン、ザミフェナシン、オキシブチニン、グリコピロラート、トロスピウム、トルテロジン、フェソテロジン、レバトロパン酸、Ro−3202904、イプラトロピウム及びチオトロピウムから選択される、請求項8〜11のいずれか1項に記載の使用。
- 治療されるべき患者が粘液溶解物質も投与される、請求項8〜12のいずれか1項に記載の使用。
- 前記粘液溶解物質がメントール又はユーカリ油である、請求項13に記載の使用。
- 前記薬物が前記粘液溶解物質を含んで成る、請求項13又は14に記載の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0602855.9 | 2006-02-13 | ||
GB0602857A GB0602857D0 (en) | 2006-02-13 | 2006-02-13 | The treatment of sialorrhoea |
GB0602857.5 | 2006-02-13 | ||
GB0602855A GB0602855D0 (en) | 2006-02-13 | 2006-02-13 | The Treatment Of Sialorrhoea |
PCT/GB2007/050057 WO2007093824A1 (en) | 2006-02-13 | 2007-02-12 | Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013064062A Division JP5744947B2 (ja) | 2006-02-13 | 2013-03-26 | 流涎症の治療のためのアルファ−2受容体アゴニスト(クロニジン)と抗ムスカリン剤(オキシブチニン)との組み合わせ |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009526829A true JP2009526829A (ja) | 2009-07-23 |
JP5296557B2 JP5296557B2 (ja) | 2013-09-25 |
Family
ID=37944141
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008554857A Active JP5296557B2 (ja) | 2006-02-13 | 2007-02-12 | 流涎症の治療のためのアルファ−2受容体アゴニスト(クロニジン)と抗ムスカリン剤(オキシブチニン)との組み合わせ |
JP2013064062A Active JP5744947B2 (ja) | 2006-02-13 | 2013-03-26 | 流涎症の治療のためのアルファ−2受容体アゴニスト(クロニジン)と抗ムスカリン剤(オキシブチニン)との組み合わせ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013064062A Active JP5744947B2 (ja) | 2006-02-13 | 2013-03-26 | 流涎症の治療のためのアルファ−2受容体アゴニスト(クロニジン)と抗ムスカリン剤(オキシブチニン)との組み合わせ |
Country Status (13)
Country | Link |
---|---|
US (2) | US8481583B2 (ja) |
EP (2) | EP2526943B1 (ja) |
JP (2) | JP5296557B2 (ja) |
KR (1) | KR101370096B1 (ja) |
AU (1) | AU2007216320B2 (ja) |
CA (1) | CA2642850C (ja) |
DK (2) | DK2526943T3 (ja) |
ES (2) | ES2624577T3 (ja) |
HK (1) | HK1129595A1 (ja) |
MY (1) | MY145817A (ja) |
NZ (1) | NZ570492A (ja) |
PT (2) | PT2526943T (ja) |
WO (1) | WO2007093824A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017534613A (ja) * | 2014-10-15 | 2017-11-24 | バイオエクセル コーポレーション | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 |
US10792246B2 (en) | 2018-06-27 | 2020-10-06 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
US11786508B2 (en) | 2016-12-31 | 2023-10-17 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
US11890272B2 (en) | 2019-07-19 | 2024-02-06 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ570492A (en) | 2006-02-13 | 2011-08-26 | Orient Pharma Samoa Co Ltd | Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling |
GB0715790D0 (en) * | 2007-08-13 | 2007-09-26 | Summit Corp Plc | Drug combination for the treatment of sialorrhoea |
US20090246256A1 (en) * | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Compositions and Methods for Transmucosal Delivery of Lofexidine |
KR20110114552A (ko) * | 2009-02-11 | 2011-10-19 | 헤글런드, 에이.에스. | 금연을 목적으로 하는 니코틴의 구강 흡수용 조성물 |
CN106511273A (zh) * | 2009-05-15 | 2017-03-22 | 瑞克欧制药有限公司 | 舌下右美托咪定组合物及其使用方法 |
WO2013090278A2 (en) | 2011-12-11 | 2013-06-20 | Recro Pharma, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
CN111093648A (zh) * | 2017-07-20 | 2020-05-01 | 艾伦实验室股份有限公司 | 治疗近视的组合物和方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064821A1 (en) * | 2003-01-22 | 2004-08-05 | Pfizer Health Ab | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4312879A (en) * | 1980-08-14 | 1982-01-26 | Richardson-Merrell Inc. | Clonidine and lofexidine as antidiarrheal agents |
US5578295A (en) * | 1995-04-28 | 1996-11-26 | The Procter & Gamble Company | Oral care compositions comprising certain substituted diphenyl ethers |
AU1155399A (en) * | 1998-06-11 | 1999-12-30 | Arthur Janov | Use of clonidine for treatment of addictions, epilepsy, sleep disorders, eating disorders and migraines |
WO2001008681A1 (en) | 1999-08-02 | 2001-02-08 | First Horizon Pharmaceutical Corporation | Methods of administration of glycopyrrolate compositions |
US6545046B2 (en) * | 2000-08-30 | 2003-04-08 | Theramax Inc. | Method for enhanced delivery of oxybutynin and compositions thereof |
NZ570492A (en) | 2006-02-13 | 2011-08-26 | Orient Pharma Samoa Co Ltd | Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling |
GB0611241D0 (en) | 2006-06-07 | 2006-07-19 | Daniolabs Ltd | The treatment of increased sebum production |
-
2007
- 2007-02-12 NZ NZ570492A patent/NZ570492A/en not_active IP Right Cessation
- 2007-02-12 EP EP12181773.8A patent/EP2526943B1/en active Active
- 2007-02-12 ES ES12181773.8T patent/ES2624577T3/es active Active
- 2007-02-12 DK DK12181773.8T patent/DK2526943T3/en active
- 2007-02-12 AU AU2007216320A patent/AU2007216320B2/en not_active Ceased
- 2007-02-12 CA CA2642850A patent/CA2642850C/en not_active Expired - Fee Related
- 2007-02-12 PT PT121817738T patent/PT2526943T/pt unknown
- 2007-02-12 JP JP2008554857A patent/JP5296557B2/ja active Active
- 2007-02-12 ES ES07705370.0T patent/ES2442694T3/es active Active
- 2007-02-12 US US12/279,217 patent/US8481583B2/en active Active
- 2007-02-12 DK DK07705370.0T patent/DK1986642T3/da active
- 2007-02-12 PT PT77053700T patent/PT1986642E/pt unknown
- 2007-02-12 KR KR1020087022049A patent/KR101370096B1/ko active IP Right Grant
- 2007-02-12 WO PCT/GB2007/050057 patent/WO2007093824A1/en active Application Filing
- 2007-02-12 EP EP07705370.0A patent/EP1986642B1/en active Active
- 2007-02-12 MY MYPI20083081A patent/MY145817A/en unknown
-
2009
- 2009-09-15 HK HK09108445.5A patent/HK1129595A1/zh not_active IP Right Cessation
-
2012
- 2012-08-23 US US13/593,173 patent/US8658683B2/en active Active - Reinstated
-
2013
- 2013-03-26 JP JP2013064062A patent/JP5744947B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064821A1 (en) * | 2003-01-22 | 2004-08-05 | Pfizer Health Ab | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders |
Non-Patent Citations (2)
Title |
---|
JPN5008024935; ROGERS DONALD P: PHARMACOTHERAPY V20 N9, 200009, P1092-1095 * |
JPN6011063428; SLEUTJES,F.M.A.M. et al: '[Speculations on sialorrhea. A side effect of clozapine]. Een bijwerking van clozapine: Speculaties' Pharmaceutisch Weekblad Vol.137, No.28, 2002, p.982-985 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017534613A (ja) * | 2014-10-15 | 2017-11-24 | バイオエクセル コーポレーション | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 |
JP2021080276A (ja) * | 2014-10-15 | 2021-05-27 | バイオエクセル セラピューティクス,インコーポレイテッド | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 |
US11931340B2 (en) | 2016-12-31 | 2024-03-19 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
US11839604B2 (en) | 2016-12-31 | 2023-12-12 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
US11786508B2 (en) | 2016-12-31 | 2023-10-17 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
US11559484B2 (en) | 2018-06-27 | 2023-01-24 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
US11517524B2 (en) | 2018-06-27 | 2022-12-06 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
US11497711B2 (en) | 2018-06-27 | 2022-11-15 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
US11806429B2 (en) | 2018-06-27 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
US11478422B2 (en) | 2018-06-27 | 2022-10-25 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
US10792246B2 (en) | 2018-06-27 | 2020-10-06 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
US11890272B2 (en) | 2019-07-19 | 2024-02-06 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
US11998529B2 (en) | 2019-07-19 | 2024-06-04 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
US11998528B1 (en) | 2023-01-12 | 2024-06-04 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Also Published As
Publication number | Publication date |
---|---|
HK1129595A1 (zh) | 2009-12-04 |
JP5296557B2 (ja) | 2013-09-25 |
PT1986642E (pt) | 2014-01-30 |
AU2007216320A1 (en) | 2007-08-23 |
US8481583B2 (en) | 2013-07-09 |
MY145817A (en) | 2012-04-30 |
DK1986642T3 (da) | 2014-02-03 |
PT2526943T (pt) | 2017-05-22 |
ES2624577T3 (es) | 2017-07-17 |
CA2642850C (en) | 2015-06-30 |
DK2526943T3 (en) | 2017-05-15 |
EP1986642A1 (en) | 2008-11-05 |
EP2526943A1 (en) | 2012-11-28 |
WO2007093824A1 (en) | 2007-08-23 |
US20090221659A1 (en) | 2009-09-03 |
JP5744947B2 (ja) | 2015-07-08 |
CA2642850A1 (en) | 2007-08-23 |
JP2013144704A (ja) | 2013-07-25 |
NZ570492A (en) | 2011-08-26 |
KR101370096B1 (ko) | 2014-03-04 |
AU2007216320B2 (en) | 2010-10-28 |
ES2442694T3 (es) | 2014-02-12 |
EP2526943B1 (en) | 2017-03-22 |
KR20090019765A (ko) | 2009-02-25 |
EP1986642B1 (en) | 2013-11-13 |
US20120316213A1 (en) | 2012-12-13 |
US8658683B2 (en) | 2014-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5744947B2 (ja) | 流涎症の治療のためのアルファ−2受容体アゴニスト(クロニジン)と抗ムスカリン剤(オキシブチニン)との組み合わせ | |
EP1933833B1 (en) | Therapy for the treatment of overactive bladder | |
ES2236189T3 (es) | Nueva combinacion de antihistaminicos no sedativos que contienen sustancias que influyen en la accion del leucotrieno, para el tratamiento de la rinitis/conjuntivitis. | |
US6376550B1 (en) | Pharmaceutical compositions containing tramadol for migraine | |
TWI419689B (zh) | 用於治療薩羅霍症(Sialorrhoea)之醫藥組合物 | |
JP2003520237A (ja) | 鬱病及び関連疾患を治療するためのミルトラザピン及びジェピロンを含有する配合剤 | |
CZ285633B6 (cs) | Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek | |
ES2237625T3 (es) | Uso de un derivado de hidantoina en una composicion farmaceutica contra la hipoalbuminemia. | |
CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
CN101400347B (zh) | α2受体激动剂(可乐定)与抗毒蕈碱药(奥昔布宁)联合用于治疗流涎 | |
CN116650482A (zh) | 3-typ在制备治疗自身免疫性脱髓鞘疾病药物中的应用 | |
Shafi et al. | Pharmacological Management of Behavior in Children | |
MX2008002907A (es) | Terapia para tratamiento de enfermedad | |
NZ617375A (en) | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120306 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120313 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120606 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130326 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130327 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130417 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130514 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130613 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5296557 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |